– USA, MA – KOMO Biosciences, Inc., a next-generation precision genome engineering technology company, announced the appointment of Martin Meeson to its Board of Directors, bringing more than two decades of industry leadership, which will be invaluable as KOMO continues to commercialize its genome engineering technology.
About Martin Meeson
His career encompasses significant roles in building and leading global contract development and manufacturing organizations, as well as biotechnology and pharmaceutical companies, where he has been pivotal in driving growth, nurturing innovation, and successfully commercializing novel therapeutics, technologies, and services.
Martin Meeson spent over 15 years at FUJIFILM Diosynth Biotechnologies, including three years as president and CEO, and is currently the CEO of Axplora, a leading global active pharmaceutical ingredient (API) CDMO. About KOMO Biosciences
KOMO Biosciences is a next-generation precision genome engineering technology company that leverages a pipeline of evolved integrases with applications in multibillion-dollar industries, including drug development, manufacturing, synthetic biology, and agricultural biotechnology. KOMO aims to enable scalable, safe, and cost-effective large cargo gene delivery solutions to address current unmet needs in genome engineering. KOMO was established in 2024 by Genesis BioCapital, a unique venture capital firm on a mission to accelerate breakthroughs in biotechnology. Other investors in KOMO include LDV Partners, Eshelman Ventures, and Modi Ventures, among others. KOMO has a dual presence in Cambridge, MA, and Honolulu, HI.
For more information: https://komobiosciences.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.